These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 22305769)

  • 1. Rodent models for HIV-associated neurocognitive disorders.
    Gorantla S; Poluektova L; Gendelman HE
    Trends Neurosci; 2012 Mar; 35(3):197-208. PubMed ID: 22305769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications.
    Hong S; Banks WA
    Brain Behav Immun; 2015 Mar; 45():1-12. PubMed ID: 25449672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-associated neurocognitive disorders (HAND).
    Elbirt D; Mahlab-Guri K; Bezalel-Rosenberg S; Gill H; Attali M; Asher I
    Isr Med Assoc J; 2015 Jan; 17(1):54-9. PubMed ID: 25739180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF penetration by antiretroviral drugs.
    Eisfeld C; Reichelt D; Evers S; Husstedt I
    CNS Drugs; 2013 Jan; 27(1):31-55. PubMed ID: 23160938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does HIV infection contribute to increased beta-amyloid synthesis and plaque formation leading to neurodegeneration and Alzheimer's disease?
    Fulop T; Witkowski JM; Larbi A; Khalil A; Herbein G; Frost EH
    J Neurovirol; 2019 Oct; 25(5):634-647. PubMed ID: 30868421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV, antiretroviral therapies, and the brain.
    Liner KJ; Ro MJ; Robertson KR
    Curr HIV/AIDS Rep; 2010 May; 7(2):85-91. PubMed ID: 20425562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.
    Clark US; Cohen RA
    Curr Opin Investig Drugs; 2010 Aug; 11(8):884-900. PubMed ID: 20721831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders.
    Gendelman HE; Gelbard HA
    Curr Opin HIV AIDS; 2014 Nov; 9(6):585-90. PubMed ID: 25226025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus-associated neurocognitive disorder: pathophysiology in relation to drug addiction.
    Nath A
    Ann N Y Acad Sci; 2010 Feb; 1187():122-8. PubMed ID: 20201849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor function and human immunodeficiency virus-associated cognitive impairment in a highly active antiretroviral therapy-era cohort.
    Robinson-Papp J; Byrd D; Mindt MR; Oden NL; Simpson DM; Morgello S;
    Arch Neurol; 2008 Aug; 65(8):1096-101. PubMed ID: 18695060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.
    Chan P; Brew BJ
    Curr HIV/AIDS Rep; 2014 Sep; 11(3):317-24. PubMed ID: 24966139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
    Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
    J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging correlates of the blood-brain barrier disruption in HIV-associated neurocognitive disorder and therapeutic implications.
    Chaganti J; Marripudi K; Staub LP; Rae CD; Gates TM; Moffat KJ; Brew BJ
    AIDS; 2019 Oct; 33(12):1843-1852. PubMed ID: 31274535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
    Bogoch II; Davis BT; Venna N
    J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.
    Peluso MJ; Spudich S
    Curr HIV/AIDS Rep; 2014 Sep; 11(3):353-62. PubMed ID: 25063356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities.
    Lindl KA; Marks DR; Kolson DL; Jordan-Sciutto KL
    J Neuroimmune Pharmacol; 2010 Sep; 5(3):294-309. PubMed ID: 20396973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-associated neurocognitive disorders: perspective on management strategies.
    Nabha L; Duong L; Timpone J
    Drugs; 2013 Jun; 73(9):893-905. PubMed ID: 23733447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropsychological Assessment of 412 HIV-Infected Individuals in São Paulo, Brazil.
    Gascón MRP; Vidal JE; Mazzaro YM; Smid J; Marcusso RMN; Capitão CG; Coutinho EM; Benute GRG; De Lucia MCS; de Oliveira ACP
    AIDS Patient Care STDS; 2018 Jan; 32(1):1-8. PubMed ID: 29323557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on HIV dementia and HIV-associated neurocognitive disorders.
    Brew BJ; Chan P
    Curr Neurol Neurosci Rep; 2014 Aug; 14(8):468. PubMed ID: 24938216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-associated neurological disorders: a guide to pharmacotherapy.
    Tan IL; McArthur JC
    CNS Drugs; 2012 Feb; 26(2):123-34. PubMed ID: 22201342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.